Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
T-Vec Vs. Oncosec (Old article comparing the two therapies but still relevant).
http://seekingalpha.com/instablog/29879435-shallum-furbush/3564275-valuation-case-for-oncosecs-immunopulse
EUROGIN 2016 Conference
Robert H. Pierce, MD, Chief Scientific Officer, will present a lecture entitled: "Intratumoral IL-12 Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC)" during the "Updates on Immunotherapy Trials in HPV-HNSCC" session at the EUROGIN 2016 Conference on June 16 at 4:15 PM CEST at the Salzburg Congress in Salzburg, Austria.
This conference focuses on human papillomavirus infection and related cancers and fosters multidisciplinary interactions that are vital to making critical discoveries. The conference is aimed at developing a full review of current scientific developments in the field of cancer and human papillomavirus related diseases, raising the public health profile, and increasing the need for responsible health services. The program also encompasses state-of-the art science on ano-genital and head and neck cancer and provides forums to share expertise and learn from the leading experts in these fields. For more information, please visit: http://www.eurogin.com/2016/.
Maybe this will increase the volume and interest.
AACR Special Conference on Engineering and Physical Sciences in Oncology
Oncosec will present poster presentations on the advancement of their electrotherapy technology June 27th. This should be interesting to see how their investments with REV-1 and Merlin may have paid off with their next generation device. The go-anywhere catheter looks and sounds like a great strategy to reach solid tumors.
I personally would choose a few seconds of pain from electricity over having a virus injected in me and wondering what the side effects might be for years.
Oncosec has a real advantage vs. T-Vec in that they do not use a virus with Immunopulse IL-12. Punit has mentioned this again in the recent earnings call. Time will tell. I still believe in this company and am willing to hold as long as it takes.
Writeup about T-Vec in combo with Merck. T-Vec data was a Phase 3 trial. Peak sales estimated to be around 500 mil. So far Oncosec results are better than T-Vec. If those results carry over to a larger Phase 3 combo trial Oncosec should at least match the same sort of interest that T-Vec has garnered...and translate into a much higher share price for Oncosec.
http://www.fool.com/investing/2016/06/13/tricking-the-common-cold-into-destroying-cancer.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
Good results from the combo p2b will lead to a phase 3 registration trial and designed for accelerated approval according to their latest investor pack. T-Vec trial was a phase 3 trial with nearly 300 people but if response rates are as good or better than T-Vec in a larger study with barely any side affects I think that Oncosec would deserve a much larger market cap than 30 million. Maybe this takes another 2 years but in the end this is heading in the right direction.
Robert Andtbacka, MD, CM, is an associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine and a surgeon at Huntsman Cancer Institute. Dr. Andtbacka is recognized as a leader in intratumoral immunotherapies, and he was pivotal in the approval of Amgen’s oncolytica virus therapy, T-VEC, for melanoma.
Robert Andtbacka is now listed as a clinical and scientific advisor to Oncosec in their most updated investor download pack.
T-VEC scored big with Amgen buyout (worth 1 Billion) and Oncosec will follow after combo results this fall. Oncosec only has a 30 million market cap equal to the amount of cash they have and no debt.
oncosec.com/QR-Downloads/ONCS-Power-Point-Presentation_Web.pdf
Maybe JNJ, Medtronic, or Abbott would be interested in Oncosec based on medical device interest.
Oncosec has a pdf displaying the new device on there website. It is listed under Technology link in publications section. Not sure if this was recently added to their website or I just missed this. Looks like they made some good progress on this.
REV1 Company who has developed Oncosecs next generation go-anywhere delivery device now lists Oncosec on their clients list along with a number of other successful clients. Two of the companies listed were bought out by Medtronic and Abbott. Apparently Oncosec picked a great R&D company to work with.....Bodes well for the future. May take a while but we will get there.
The pieces will all come together soon. Looking very good now.
Even though it is a small trial it is enough to get the ball rolling in the right direction. As expected high volume off $3 mark should have this moving to the $4-$5 level soon.....Cup and Handle chart pattern looking good to me!
Merck would be foolish not to buy Oncosec if given the opportunity. But then again maybe Oncosec won't settle for an underpriced buyout.
Here we go!
Dr. Pierce talked about Oncosec technology and why he joined them in a video that used to be on Oncosec's homepage. It is no longer on the homepage and I don't see it anywhere else on the website now.
Dr. Pierce said he joined Oncosec because they had the ability to help the 60-70% of the population of non-responders to Keytruda. Dr. Pierce spent many years working on Keytruda at Merck so joining Oncosec was the next step in advancing Keytruda to a higher level using Oncosec technology. There is a huge unmet need that can be remedied and Dr. Pierce obviously saw the potential to achieve this goal at Oncosec.
I do believe that if the data from the Merck combo trial is excellent then the sky is the limit with regards to share price. A parabolic share spike could be in the cards for Oncosec. That happens all the time with speculative biotech companies. I also believe that good results will lead to other combo trials with Merck and possibly other partnerships with other companies who might be interested in a buyout of Oncosec in the future if Merck is not the buyer. Merck was willing to fork out $8 billion dollars for Cubist so who knows what an Oncosec buyout could bring in the future. It could be huge. Time will tell. Good luck to all investors here and the many lives that would be saved by innovative science brought forth by Oncosec and Merck.
Cup and Handle trading pattern still in process. Good news Sunday and Tuesday should have the stock rolling into a breakout above $3.00.....then the real fun begins into data readout on combo trial with Merck by the end of the year... and yes Oncosec doesn't have a partnership with Merck, yet. They have a collaboration as do many other companies in combo trials with Keytruda. What Oncosec has that all these other companies don't have is Dr. Pierce.....who isn't so much worried about the stock price but the science that he has invested his life in. Dr. Pierce is a firm believer in what Oncosec is trying to do. Why else would he leave Merck to join Oncosec? The stock market is manipulated every day, we all know that. When solid life-saving data is released from Oncosec the market manipulators will be left in the dust.
I would be quite happy with $25 a share too. Keep the faith!
Absolutely I agree 100%. Merck will buyout Oncosec when the data comes out. Merkel Cell and Head and Neck cancer indications will be rebooted later on after a buyout because Merck is into all that too but PD-1 is all important in the near term.
Johnson and Johnson's Ethicon division just acquired NeuWave Medical Inc., a maker of cancer-killing devices (zaps cancer tumors with microwaves). Big pharma has been opening up to alternative cancer treatments and Oncosec will get their turn to shine in the spotlight soon when the data comes out.
Here comes the cup and handle breakout folks. Grab your popcorn.
I think we are in good shape here. I think between now and the release of data in April we get the cup and handle breakout we are looking for.
Exciting to watch the turnaround here with ONCS. Patience is still key with this type of investment. Slansky made it pretty clear in his recent interview that Oncosec is being primed for a buyout in the future. Too much long-term value to pass up here when big pharma finally takes the plunge and invests big money.
Bullish Cup and Handle pattern continues to play out. After this hits $3.00 again we should be on target for $4.50.
Bullish Cup and Handle pattern looking pretty clear with the handle in process. Good data next month should have this breaking to the $4-$5 level. The million shares traded at the $3 level last week was extremely bullish.
3 month and 6 month charts are looking like a classic cup and handle pattern.
Oncosec presentation starts at around 6:25:00 on the youtube video.
Link to todays SACHS presentation.
I am hoping that Baker Bros. or New Leaf Venture Partners pops up on the holdings list at some point. That would be sweet!
I haven't done a side by side comparison of both sites but Ridgeback, Sabby, and Vanguard are still the most significant holders. The fact that smaller positions are slowly popping up is a positive and I wouldn't be surprised to see these holdings increase substantially as any more news starts coming out this year. I have been holding stock in Oncosec for over 2 years now and am just as excited about their longer term prospects and the future direction of cancer treatments with regards to combo work with Merck. Dr. Pierce working with Oncosec is the only reason I had faith in the first place and still keep that faith. Patience is key here.
I'm looking on Morningstar website and CNN.com site. Ridgeback and Sabby are still largest holders followed by Vanguard which has increased their Extended market holdings. On Cnn.com their are a handful of smaller investments made in the last quarter. Slowly funds are adding to Oncosec. Looks good to me.
SEC filing yesterday on ONCOSEC website shows Ridgeback Capital Management LP still holding its position plus adding more shares- total is now 1,292,614 shares.
New Vanguard positions in Oncs listed on Morningstar.com website.
Vanguard Total Stock Mkt Index- 370,200 shares
also Vanguard Extended Market Index- 6,600 shares
Vanguard Total Stock Mkt Index is now listed holding 370,200 shares of Oncs. This will blow up eventually. Patience is key to this investment.
Here is an interesting interview with Dr. Pierce with Ascopost.com
Not sure if anybody has posted this before.
http://www.ascopost.com/issues/march-10,-2015/determining-why-not-all-patients-respond-to-pd-1-inhibitors.aspx
ClinicalTrials.gov lists Merkel Cell Cancer study estimated completion date as June 2015.
Wondering if anybody has any new information on Oncosec Merkel Cell study.
https://www.clinicaltrials.gov/ct2/show/results/NCT01440816?term=merkel+cell+carcinoma
Just curious where ONCS closed today. Yahoo shows .56 at 4:44 pm. Scottrade shows .545. After hours trading on an OTC stock?
Not that it matters much because this stock should rocket sooner or later.
Zacks has raised ONCS to Buy Rating and a $1.50 12 month target price. That would be a nice gain from this level.
A post on Yahoo Board mentions ROTH has an offering monday morning for ONCS at $1.30.
Anybody have any news on this?